title: High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma.
abstract: BACKGROUND
  Autologous stem cell transplantation (ASCT) generally provides good results in Hodgkin's lymphoma (HL). We studied a high-dose chemotherapy regimen based on thiotepa, etoposide and carboplatin (TECA).
  
  
  METHODS
  Fifty-eight patients with advanced HL  were treated with thiotepa, etoposide and carboplatin for transplant induction.
  
  
  RESULTS
  The overall response rate was 79·3% (39 CR: 67·2%; and 7 PR: 12·1%); 12 patients (20·1%) were non-responders. The 5-year overall survival rate was 77·6%; five  initially responder patients relapsed within the first 5 years of follow-up and underwent salvage therapy.
  
  
  CONCLUSIONS
  The TECA conditioning regimen for ASCT in HL results in a good anti-HL effect, positive response to treatment and high 5-year overall survival rate. It was also  well tolerated and did not induce excessive toxicity, suggesting that TECA may be a very useful conditioning regimen for HL.
authors.affiliation: Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, University of Perugia Medical School, I-06100 Perugia, Italy.
authors.forename: Mauro
authors.initials: M
authors.lastname: Di Ianni
authors.forename: Stelvio
authors.initials: S
authors.lastname: Ballanti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Iodice
authors.forename: Antonia
authors.initials: A
authors.lastname: Reale
authors.forename: Franca
authors.initials: F
authors.lastname: Falzetti
authors.forename: Olivia
authors.initials: O
authors.lastname: Minelli
authors.forename: Gabriella
authors.initials: G
authors.lastname: Serio
authors.forename: Massimo F
authors.initials: MF
authors.lastname: Martelli
authors.forename: Franco
authors.initials: F
authors.lastname: Dammacco
authors.forename: Angelo
authors.initials: A
authors.lastname: Vacca
authors.forename: Roberto
authors.initials: R
authors.lastname: Ria
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D015996:Survival Rate; D013852:Thiotepa / Q000008:administration & dosage; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D004317:Doxorubicin; D013852:Thiotepa; D016190:Carboplatin